LSI Alumni Funding Report May 2025

May was another impressive month of funding for the LSI Alumni, raising over $120 million in new capital across 13 new deals. Our monthly Alumni Funding Update features transactions made by these medical device startups and their investors, as well as links to our proprietary media and coverage of the companies themselves.

Companies featured in the May 2025 update include:

Accelus

Obtained new growth funding led by Concord Health Partners to drive commercial scaling and advance the development of its expandable spinal implant portfolio. The company also named seasoned medtech executive Bernie Haffey as Chairman of the Board to help steer its next stage of strategic expansion.

Cosm Medical

Completed the initial tranche of its Seed Extension round to fast-track commercialization of its personalized, AI-enabled 3D-printed pelvic health solutions. The funding will support post-FDA clearance growth and upcoming clinical presentations at IUGA and other major U.S. women’s health conferences.

EBR Systems

Announced a fully underwritten institutional placement to raise $36.1M in support of commercializing its WiSE CRT system — the only FDA-approved wireless cardiac pacing device for heart failure. The funding will enable a limited market launch in 2025 and scale U.S. distribution in 2026.

Hy2Care

Raised €4.5M to support U.S. clinical trial readiness and advance global expansion efforts for CartReviveⓇ, a minimally invasive hydrogel implant designed for cartilage repair. With backing from the European Innovation Council Fund and strategic investors like Brightlands Venture Partners, the funding will help accelerate post-FDA IDE preparations and pave the way for commercial entry in Europe and other markets.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/lsi-alumni-funding-report-may-2025 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more